Waypoint Bio raised $20 million in Series A financing to run multiple CAR-T trials in China, targeting both patient access and study execution through the local clinical environment. The New York City startup said the funding will support parallel cell therapy efforts under China’s testing framework. The company’s focus on CAR-T in China reflects a strategy to accelerate trial timelines while preserving global optionality for later development. For sponsors considering geographies, the round reinforces the continuing appetite for China-based early clinical infrastructure. While the specific trial targets weren’t detailed in the summary provided, the stated objective is to expand CAR-T testing across multiple studies rather than focus on a single program. The funding highlights how startups are using staged capital to reduce execution risk in cell therapy development, where manufacturing and trial logistics can make timelines a primary bottleneck.